Gracell Biotechnologies (GRCL) Earnings

In its last earnings report on August 12, 2024, Gracell Biotechnologies reported earnings per share (EPS) of $, compared to an estimated EPS of $. The company reported revenue of $-, compared to an estimated revenue of $-.

Gracell Biotechnologies's current Price-to-Earnings (P/E) ratio is -2.81. The trailing twelve months (TTM) P/E ratio is -29.24. The P/E ratio is a valuation metric that compares a company's current share price to its earnings per share (EPS). A higher P/E ratio suggests that investors are expecting higher earnings growth in the future compared to companies with a lower P/E ratio.

For the fiscal year ending December 31, 2022, Gracell Biotechnologies reported total revenue of $- and net income of $-607.51M. This represents a net profit margin of 0.

Gracell Biotechnologies's earnings yield is -35.63%. The earnings yield is the inverse of the P/E ratio and represents the percentage of each dollar invested in the stock that was earned by the company.

Gracell Biotechnologies's return on equity (ROE) is -44.16%. ROE is a measure of financial performance calculated by dividing net income by shareholders' equity. It measures how effectively management is using a company's assets to create profits.

Gracell Biotechnologies's gross profit margin is 0.00%. This indicates that for every dollar of revenue, the company retains $0.00 as gross profit after accounting for the cost of goods sold.